Last reviewed · How we verify
FMX101, Minocycline 4% foam
At a glance
| Generic name | FMX101, Minocycline 4% foam |
|---|---|
| Also known as | FMX101 antibiotic foam |
| Sponsor | Vyne Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne Vulgaris (PHASE3)
- A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris (PHASE4)
- A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris (PHASE3)
- A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne (PHASE3)
- A Pharmacokinetic Study of Minocycline in Male and Female Volunteers (PHASE1)
- Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients (PHASE2)
- Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FMX101, Minocycline 4% foam CI brief — competitive landscape report
- FMX101, Minocycline 4% foam updates RSS · CI watch RSS
- Vyne Therapeutics Inc. portfolio CI